Hagop M. Kantarjian

Statistics

Publications

2.1K

Citations

226.5K

H-Index

216

Active since

1983

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Dana-Farber Cancer Institute

Hagop M. Kantarjian is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and hematologic malignancy therapy.

ORCID

Publications per year

1983–2025

2.1K

Publications

2.1K

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Brian Druker, Moshe Talpaz, Debra Resta et al. · New England Journal of Medicine · 2001 · 5.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Stephen G. O’Brien, François Guilhot, Richard A. Larson et al. · New England Journal of Medicine · 2003 · 3.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

Medicine, Hematology, Oncology +13

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Peter L. Greenberg, Heinz Tuechler, Julie Schanz et al. · Blood · 2012 · 3.1K citations · Full text

Medicine, Hematology, Internal Medicine +12

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

Brian Druker, Charles L. Sawyers, Hagop M. Kantarjian et al. · New England Journal of Medicine · 2001 · 2.7K citations · Full text

Medicine, Hematology, Oncology +17

1–5 of 2.1K